iCAD (NASDAQ:ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced clearance by the United States Food and Drug Administration (FDA) for their latest, deep-learning, cancer detection software solution for digital breast tomosynthesis (DBT), ProFound AI™, clearing the technology for commercial sales and clinical use in the United States. As quoted in … Continued
The post iCAD Announces FDA Clearance of ProFound AI for Digital Breast Tomosynthesis appeared first on Investing News Network.